Federico Mazzotti

Federico Mazzotti

Auto-generated profile, based on publicly available information

Federico Mazzotti

Colorectal and General Surgery Unit, Ospedale per gli Infermi Faenza and Ospedale Santa Maria delle Croci Ravenna, AUSL Romagna, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Radiology
Verified
Journal Article
Closed access
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
SBStefano Brocchi
Stefano Brocchi
ACAlessandro Cucchetti
Alessandro Cucchetti
FMFederico Mazzotti
Federico Mazzotti
Cristina MosconiCristina Mosconi
Cristina Mosconi
Rita GolfieriRita Golfieri
Rita Golfieri
Some “worrisome” imaging features, such as nonsmooth tumor margins, peritumoral enhancement, two-trait predictor of venous invasion (“internal arteries” and “hypoattenuating halos”), and large tumor size were used to significantly predict the presence of microvascular invasion in hepatocellular carcinoma. PurposeTo determine the accuracy of imaging features, such as tumor dimension, multinodularity, nonsmooth tumor margins, peritumoral enhancement, and radiogenomic algorithm based on the association between imaging features (internal arteries and hypoattenuating halos) and gene expression that the authors called two-trait predictor of venous invasion (TTPVI), in the prediction of microvascular invasion (MVI) in hepatocellular carcinoma (HCC).Materials and MethodsThis single-center retrospective study was approved by the institutional review board, and the requirement for informed consent was waived. One hundred twenty-five patients (median age, 63 years; interquartile range, 53–71 years) with a diagnosis of HCC and indications for hepatic resection were included. Two observers independently reviewed radiologic images to evaluate the following features for MVI: maximum diameter, number of lesions, tumor margins, TTPVI, and peritumoral enhancement. Interobserver agreement was checked, and diagnostic accuracy...

1 January 2016 in Journal of Hepatology
Verified
Journal Article
Closed access
ACAlessandro Cucchetti
Alessandro Cucchetti
MCMatteo Cescon
Matteo Cescon
Rita GolfieriRita Golfieri
Rita Golfieri
FPFabio Piscaglia
Fabio Piscaglia
Matteo RenzulliMatteo Renzulli
Matteo Renzulli
APAntonio Daniele Pinna
Antonio Daniele Pinna

15 November 2014 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
ACAlessandro Cucchetti
Alessandro Cucchetti
AFAlessandro Ferrero
Alessandro Ferrero
Matteo CesconMatteo Cescon
Matteo Cescon
MDMatteo Donadon
Matteo Donadon
NRNadia Russolillo
Nadia Russolillo
APAntonio Daniele Pinna
Antonio Daniele Pinna

1 April 2017 in Liver Cancer
Verified
Journal Article
Open access
PDF file
ACAlessandro Cucchetti
Alessandro Cucchetti
FPFabio Piscaglia
Fabio Piscaglia
APAntonio Daniele Pinna
Antonio Daniele Pinna
BDBenjamin Djulbegovic
Benjamin Djulbegovic
FMFederico Mazzotti
Federico Mazzotti
LBLuigi Bolondi
Luigi Bolondi
Aim/Background: After the introduction of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC), different studies tried to evaluate whether other systemic therapies can improve survival. To provide a comprehensive indirect treatment comparison of efficacy and safety of novel drugs, a network meta-analysis (NMA) of phase III randomized controlled trials was performed. Methods: After pertinent literature search up to November 1, 2016, 6 studies were eligible for the analysis including 4,812 individual patients with advanced HCC: 2,454 received sorafenib, 577 received brivanib, 530 received sunitinib, 514 received linifanib, 358 received sorafenib + erlotinib and 379 received placebo. Frequentist NMA was used to compare treatments within a single analytical framework. Results: NMA showed that sorafenib alone, regardless of combination with erlotinib, and linifanib provide a significant survival advantage over placebo (p < 0.05) but without any significant difference between each other. Conversely, all regimens significantly ameliorate progression-free survival versus placebo (p < 0.05). The rank order of efficacy was: sorafenib ± erlotinib, linifanib, brivanib, sunitinib, and placebo. Sorafenib ± erlotinib was the regimen with the fewest number of adverse events that required discontinuation of treatment, whereas linifanib and brivanib resulted in the most adverse events. The risk-benefit summary identified one cluster of therapies with a similar balance between efficacy and safety which included sorafenib alone or in combination with erlotinib, having, at the same time, the highest efficacy and safety. Conclusions: Sorafenib remains the best systemic treatment for advanced HCC; linifanib also resulted in survival advantages over placebo but with a lower safety profile.

8 November 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
GTGiovanni Taffurelli
Giovanni Taffurelli
IMIsacco Montroni
Isacco Montroni
FGFederico Ghignone
Federico Ghignone
DZDavide Zattoni
Davide Zattoni
AGAnna Garutti
Anna Garutti
GUGiampaolo Ugolini
Giampaolo Ugolini

1 October 2013 in The American Journal of Surgery
Verified
Journal Article
Closed access
ACAlessandro Cucchetti
Alessandro Cucchetti
FMFederico Mazzotti
Federico Mazzotti
SPSara Pellegrini
Sara Pellegrini
Matteo CesconMatteo Cescon
Matteo Cescon
LMLorenzo Maroni
Lorenzo Maroni
APAntonio Daniele Pinna
Antonio Daniele Pinna